Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-adapted bevacizumab-based chemotherapy in first-line unresectable metastatic colorectal cancer
2023-507873-16-00Phase 4Authorised
- Sponsor
- CHRU Tours
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bevacizumab in colorectal cancer (CRC) (3 arms), sponsored by CHRU Tours. Primary endpoint: Progression-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-507873-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507873-16-00.